Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSirnaomics-B
Stock Code02257
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家RNA療法生物製藥公司,候選產品處於臨床前及臨床階段,專注於探索及開發創新藥物,用於治療存在醫療需求及龐大市場機會的適應症。擁有專有的多肽納米顆粒(PNP)遞送平台及新型GalNAc RNAi遞送平台,核心產品STP705已在腫瘤學領域取得積極IIa期臨床結果。
Listing Date2021-12-30
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)蘇州工業園星湖街218號A4樓415室
Business Address (Hong Kong)香港灣仔皇后大道東183號合和中心46樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.sirnaomics.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 65.90 / shares
Offer Price RangeFinal offer price only, no range
Lot Size50 shares
Entry ThresholdHK$ 3,295
Par ValueRMB 0.001 / shares
Offer Period2021-12-20 to 2021-12-23
Global Offering Shares7,540,000 shares
HK Public Offer Shares (Initial)754,000 shares (10.0%)
Public Offer Lots (Initial)15,080lots (Pool A7,540lots,Pool B7,540lots)
International Placing Shares (Initial)6,786,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO88,066,780 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share44.9%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 496,886,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 50 HK$ 3,295
2 lots 100 HK$ 6,590
3 lots 150 HK$ 9,885
4 lots 200 HK$ 13,180
5 lots 250 HK$ 16,475
6 lots 300 HK$ 19,770
7 lots 350 HK$ 23,065
8 lots 400 HK$ 26,360
9 lots 450 HK$ 29,655
10 lots 500 HK$ 32,950
12 lots 600 HK$ 39,540
14 lots 700 HK$ 46,130
16 lots 800 HK$ 52,720
18 lots 900 HK$ 59,310
20 lots 1,000 HK$ 65,900
30 lots 1,500 HK$ 98,850
40 lots 2,000 HK$ 131,800
50 lots 2,500 HK$ 164,750
60 lots 3,000 HK$ 197,700
70 lots 3,500 HK$ 230,650
80 lots 4,000 HK$ 263,600
90 lots 4,500 HK$ 296,550
100 lots 5,000 HK$ 329,500
120 lots 6,000 HK$ 395,400
140 lots 7,000 HK$ 461,300
160 lots 8,000 HK$ 527,200
200 lots 10,000 HK$ 659,000
400 lots 20,000 HK$ 1,318,000
600 lots 30,000 HK$ 1,977,000
800 lots 40,000 HK$ 2,636,000
1,000 lots 50,000 HK$ 3,295,000
1,200 lots 60,000 HK$ 3,954,000
1,400 lots 70,000 HK$ 4,613,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,800 lots 90,000 HK$ 5,931,000
2,000 lots 100,000 HK$ 6,590,000
4,000 lots 200,000 HK$ 13,180,000
7,540 lots 377,000 HK$ 24,844,300

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 600.8M
Est. Threshold HK$ 9.37B
Analysis Result HK market cap below threshold, need +1460%

Valuation & Financials

Market Cap (at Offer Price)HK$ 5,803,600,802
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损约46.4百万美元
Period-End Cash Balance美元103.1百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 USD
Income Statement
Item 20192020591959205939692079207939
Profit before tax -71,527-96,428
Income tax expense 00
Profit for the year -71,627-96,628
Profit attributable to owners -93,372-96,381
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 77.9
First Day OpenHK$ 65.9
First Day Change18.21%
First Day Volume1252800.0
First Day Turnover86073700.0
Use of Proceeds
1、約229.1百萬港元(相當于約29.4百萬美元,占所得款項凈額的57.9%)將用于撥付發展及商業化STP705; 2、約61.8百萬港元(相當于約7.9百萬美元,占所得款項凈額的15.6%)將用于撥付STP707的開發; 3、約60.7百萬港元(相當于約7.8百萬美元,占所得款項凈額的15.4%)將用于撥付我們的GalNAc計劃產品,以及其他臨床前階段候選產品; 4、約29.1百萬港元(相當于約3.7百萬美元,占所得款項凈額的7.3%)將用于撥付其他臨床前候選藥物的研發; 5、約15.0百萬港元(相當于約1.9百萬美元,占所得款項凈額的3.8%)將用于一般企業及營運資金用途。

Underwriting Syndicate

Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (5)
中国国际金融香港证券有限公司 CE AEN894 香港上海汇丰银行有限公司 CE AAA523 Nomura International (Hong Kong) Limited CE AAF742 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 PING AN SECURITIES (HONG KONG) COMPANY LIMITED CE BMC491
Joint Bookrunners (7)
中国国际金融香港证券有限公司 CE AEN894 香港上海汇丰银行有限公司 CE AAA523 Nomura International (Hong Kong) Limited CE AAF742 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 PING AN SECURITIES (HONG KONG) COMPANY LIMITED CE BMC491 Alpha Win Capital Limited CE BNI045 VALUABLE CAPITAL LIMITED CE AUL711

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 昆明佳时清投资合伙企业(有限合伙) 183,956,555 HKD — 37.02% — 6 months 2022-06-30
2 浙江健新原力制药有限公司 38,969,965 HKD — 7.84% — 6 months 2022-06-30

Directors & Management

PositionChinese nameEnglish Name
Chairman陸陽—
Company Secretary張蘊—
No director data available.

Major Shareholders

Major Shareholders & Holdings陸博士持股14.36%,戴曉暢博士持股9.42%(緊隨全球發售完成後,假設超額配股權未獲行使)
About this page

This page shows Sirnaomics-B (02257) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect